A number of clinical studies have been conducted on PD-1 mAbs combined with other chemotherapeutic drugs in the treatment of AML, such as cytarabine (116), azacytidine (117), decitabine (118), and these treatment regimens are clinically feasible and have shown encouraging results. Here, PDCD1 is linked to acute myeloid leukemia.